Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis

J Infect Chemother. 2015 Aug;21(8):559-63. doi: 10.1016/j.jiac.2015.04.008. Epub 2015 Apr 29.

Abstract

Chronic kidney disease (CKD) is an increased risk for the development of active tuberculosis, but few studies have analyzed the treatment outcome of pulmonary tuberculosis among CKD patients. A retrospective cohort study was conducted at Chiba-East Hospital in Chiba, Japan. Our study estimated the treatment outcomes in smear-positive pulmonary tuberculosis in relation to CKD and its stages. Total subjects were 759 patients (12-99 years) hospitalized between 2007 and 2012. Patients suffering from multi-drug-resistant tuberculosis were excluded. Patients with CKD were 19.3% aged <65 years (n = 384), and 49.6% aged ≥ 65 years, respectively (P < 0.001). Successful treatment was 52.7% in CKD (n = 260) and 67.3% in non-CKD (n = 499) (P < 0.001). Death was 25.4% in CKD and 12.4% in non-CKD (P < 0.001). Treatment outcome was especially poor in patients with low estimated glomerular filtration rate (eGFR) of <30 ml/min/1.73 m(2), as successful treatment was 20.0%, and death was 50.0%, significantly lower than in other CKD and non-CKD patients. After multivariate logistic regression analysis, eGFR<30 ml/min/1.73 m(2) was an independent factor affecting successful treatment and death, and its adjusted odds ratios (aOR) were 0.20 (95% confidence interval (CI) 0.07-0.50) and 2.99 (95%CI 1.20-7.51), respectively. Other factors affecting successful treatment were serum albumin <3.0 mg/dl, steroid therapy for underlying disease and cardiovascular disease, with aOR (95%CI) of 0.28 (0.20-0.39), 0.32 (0.16-0.63) and 0.49 (0.28-0.86), respectively. Several factors were associated with poor treatment outcome of smear-positive pulmonary tuberculosis. Advanced stage of CKD with eGFR of <30 ml/min/1.73 m(2) was a risk factor for poor treatment outcome.

Keywords: Chronic kidney disease; Mycobacterium tuberculosis; Pulmonary tuberculosis; Treatment outcome; eGFR TEXT.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antitubercular Agents / therapeutic use*
  • Cardiovascular Diseases / epidemiology
  • Child
  • Drug Therapy, Combination
  • Ethambutol / therapeutic use
  • Female
  • Glomerular Filtration Rate*
  • Humans
  • Isoniazid / therapeutic use
  • Japan / epidemiology
  • Male
  • Middle Aged
  • Pyrazinamide / therapeutic use
  • Renal Insufficiency, Chronic / complications
  • Renal Insufficiency, Chronic / physiopathology*
  • Retrospective Studies
  • Rifampin / therapeutic use
  • Risk Factors
  • Serum Albumin / metabolism
  • Sputum / microbiology
  • Steroids / therapeutic use
  • Streptomycin / therapeutic use
  • Survival Rate
  • Treatment Outcome
  • Tuberculosis, Pulmonary / complications
  • Tuberculosis, Pulmonary / drug therapy*
  • Tuberculosis, Pulmonary / mortality*
  • Young Adult

Substances

  • Antitubercular Agents
  • Serum Albumin
  • Steroids
  • Pyrazinamide
  • Ethambutol
  • Isoniazid
  • Rifampin
  • Streptomycin